Oragenics opened lower at $0.34, compared with its previous close of $0.34. In the last trading session, the stock traded between $0.34 and $0.38. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Oragenics is now worth
$ 0.03
Resulting in a loss of
$ 99.97 (99.97%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.02 (+4.95%)
Day High
$0.38
Day Low
$0.34
Day Open
$0.34
Prev Close
$0.34
Volume
7,290
1W Return
-4.53%
1M Return
-20.27%
3M Return
-33.95%
6M Return
-35.80%
1Y Return
-68.32%
Fundamentals
Market Cap ($ Mn)
2
PE Ratio
-
PB Ratio
0.64
PEG Ratio
-
ROE
-309.30%
ROCE
-294.63%
EPS (TTM)
$-0.56
Investment Returns
1 Week
-4.53%
1 Month
-20.27%
3 Months
-33.95%
6 Months
-35.80%
9 Months
-46.00%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
16Sep
Oragenics CMO to present ONP-002 concussion data at IPAC-RS forum
James P. Kelly, CMO of Oragenics, to present ONP-002 data at IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. ONP-002 is a first-in-class intranasal neurosteroid candidate for treating mild traumatic brain injury (concussion). Phase IIa feasibility trial is currently enrolling at three sites in Australia. Company anticipates submitting Investigational New Drug (IND) application in Q4 2026 for U.S. development. Phase I safety trials completed with favorable profile; no current FDA-approved pharmacological treatments exist for mTBI.
1mo ago
29Aug
Oragenics doses 9 in Phase IIa trial; receives NYSE deficiency letter
Oragenics dosed nine participants in its Australian Phase IIa trial for ONP-002 across three active sites. The company received a NYSE deficiency letter on August 26, 2026, citing non-compliance with stockholders' equity standards. Oragenics has 45 days to submit a compliance plan to avoid delisting procedures before February 25, 2028. The firm aims to submit an Investigational New Drug application to the FDA by the end of 2026.
